The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.
The global human insulin market exhibited moderate growth during 2015-2020. Looking forward, IMARC Group expects the market to grow at a CAGR of around 5% during 2021-2026. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic. These insights are included in the report as a major market contributor.
Human insulin (HI) is a form of synthetic insulin that is synthesized in laboratories for pharmaceutical use. It is bio-engineered by growing insulin proteins within E-coli bacteria (Escherichia coli) cells to mimic the properties of insulin naturally present in humans. The HI drugs are available in three kinds, namely rapid-acting, long-acting and premixed. They are used as a solution or suspension and are usually injected subcutaneously and aid in promoting the uptake of glucose from the blood into internal organs, such as fat cells, skeletal muscles and liver. They also inhibit hepatic glucose production, lipolysis and proteolysis and enhance protein synthesis in the body.
The increasing prevalence of obesity and diabetes across the globe is one of the key factors driving the growth of the market. Owing to sedentary lifestyles, growing geriatric population and unhealthy dietary habits, a greater number of individuals are suffering from chronic lifestyle diseases, thereby increasing the demand for insulin therapeutics. Furthermore, the growing requirement for biosimilar drugs, owing to their high efficiency and cost-effectiveness, is providing a boost to the market growth. Various technological advancements, such as the development of pen devices and safety pen needles, to administer HI in the body, are also creating a positive impact on the market growth. In comparison to standard needles, these safety pens ensure minimal injuries, discomfort and infections through bloodborne pathogen transmission. Other factors, including the increasing health consciousness among the masses and extensive research and development (R&D) in the field of biotechnology, are projected to drive the market further.
IMARC Group provides an analysis of the key trends in each sub-segment of the global human insulin market report, along with forecasts for growth at the global, regional and country level from 2021-2026. Our report has categorized the market based on product type, distribution channel and disease type.
Breakup by Product Type:
Breakup by Distribution Channel:
Breakup by Disease Type:
Breakup by Region:
The competitive landscape of the industry has also been examined with some of the key players being B. Braun Melsungen AG, Becton Dickinson & Company, Biocon, Eli Lilly and Company, Julphar, Novo Nordisk, Pfizer, Sanofi, Sedico, Wockhardt, Ypsomed Holding, etc.
|Base Year of the Analysis||2020|
|Segment Coverage||Product Type, Distribution Channel, Disease Type, Region|
|Region Covered||Asia Pacific, Europe, North America, Latin America, Middle East and Africa|
|Countries Covered||United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico|
|Companies Covered||B. Braun Melsungen AG, Becton Dickinson & Company, Biocon, Eli Lilly and Company, Julphar, Novo Nordisk, Pfizer, Sanofi, Sedico, Wockhardt and Ypsomed Holding|
|Customization Scope||10% Free Customization|
|Report Price and Purchase Option||Single User License: US$ 2299
Five User License: US$ 3399
Corporate License: US$ 4499
|Post-Sale Analyst Support||10-12 Weeks|
|Delivery Format||PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)|
Key Questions Answered in This Report:
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )
Drop us an email at